Evidence map›Paper›PMID 41830191›Full record

Trial reportLower urinary tract symptoms2026

Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α

Masaki Yoshida, Yoshinori Nishino, Hiroshi Nagae, Shinobu Kato, Sadaaki Sakamoto, Morifumi Hojo, Toshihide Miyauchi, Shinji Kageyama, Shinichi Takahashi, Hideya Kuroda and 12 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lower urinary tract symptoms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Masaki YoshidaDepartment of Urology, Sakurajyuji Hospital, Kumamoto, Japan.
Yoshinori NishinoNishino Clinic, Gifu, Japan.
Hiroshi NagaeNagae Prostate Care Clinic, Shizuoka, Japan.
Shinobu KatoKato Urological Clinic, Kanagawa, Japan.
Sadaaki SakamotoDepartment of Urology, Nakamura Hospital, Oita, Japan.
Morifumi HojoDepartment of Urology, Koga Hospital 21, Fukuoka, Japan.
Toshihide MiyauchiDepartment of Urology, Oita Urology Hospital, Oita, Japan.
Shinji KageyamaKageyama Clinic, Shizuoka, Japan.
Shinichi TakahashiTakahashi Urological Clinic, Oita, Japan.
Hideya KurodaKURODA UROLOGY CLINIC, Osaka, Japan.
Naoki MoriDepartment of Urology, Tagawa Municipal Hospital, Fukuoka, Japan.
Yasuhiro KasagiKasagi Urology Clinic, Oita, Japan.
Koichi MasunagaItabashi Tokumaru Clinic, Tokyo, Japan.
Yoshiyuki NabeshimaDepartment of Urology, Fukuoka Tokushukai Hospital, Fukuoka, Japan.
Masanori NomiyaDepartment of Urology, National Center for Geriatrics and Gerontology, Aichi, Japan.
Koichi IwashitaShiizako Urological Clinic, Oita, Japan.
Koichi MiyamaeMaehara Urology Clinic, Kumamoto, Japan.
Masayuki OtaniOtani Clinic, Oita, Japan.
Kazuya KawaharaKAWAHARA Nephro-Urology Clinic, Kagoshima, Japan.
Makoto IkedaMedical Affairs, Kyorin Pharmaceutical Co. Ltd., Tokyo, Japan.ORCID https://orcid.org/0009-0007-8950-6129
Shinichi KubonoMedical Department, Kissei Pharmaceutical Co. Ltd., Tokyo, Japan.
Nobuhiro HagaDepartment of Urology, Fukuoka University, Faculty of Medicine, Fukuoka, Japan.

Funding

Kissei Pharmaceutical Co. LtdKyorin Pharmaceutical Co. Ltd
6 · The paper itself

Abstract

objectivesTo evaluate the efficacy and safety of vibegron add-on therapy for persistent overactive bladder (OAB) symptoms after α

methodsEligible patients were aged ≥ 50 years and diagnosed with BPH. All patients had received an α

resultsOverall, 158 patients were randomized into two groups (n = 79 each). The least-squares mean change in the primary endpoint (OABSS total score) was -1.9 (95% confidence interval [CI]: -2.4 to -1.5) with α

conclusionsVibegron add-on therapy to an α

Indexed as

Adrenergic alpha-1 Receptor AntagonistsProstatic HyperplasiaPyrimidinonesPyrrolidinesUrinary Bladder, OveractiveAgedDrug Therapy, CombinationHumansMaleMiddle AgedPatient SatisfactionProspective StudiesTreatment OutcomeAdrenergic alpha-1 Receptor AntagonistsN-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamidePyrimidinonesPyrrolidinesadrenergic alpha‐1 receptor antagonistoveractive bladderprostatic hyperplasiarandomized controlled trialvibegronβ3‐adrenergic receptor agonist

Identifiers

PMID41830191
PMCPMC12988341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.